Phase 2 Depression and Anxiety Trial, Recruiting NCT07094503 Sponsor: Washington University School of Medicine Condition: Depression and Anxiety
Back to Depression And Anxiety

Phase 2 Depression and Anxiety Trial, Recruiting

NCT07094503
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who are between 13 and 17 years old
  • People who own a smartphone
  • People who speak English
  • People who live in the United States
  • People whose screening results show they are at risk for an eating disorder (but do not currently have one)
  • People who are not currently receiving treatment for an eating disorder

Who may not be able to join:

  • People who are younger than 13 or older than 17 years of age
  • People who do not own a smartphone
  • People who do not speak English
  • People who live outside the United States
  • People whose screening results show they already have a subclinical or clinical eating disorder
  • People whose screening results show they are not considered at risk for an eating disorder
  • People who are currently receiving treatment for an eating disorder

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 12 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Ellen Fitzsimmons-Craft, PhD, Washington University School of Medicine

Phone: 314-935-5843

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Registry
ClinicalTrials.gov
Start date
18 June 2024
Est. completion
30 May 2026

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

ED risk factors; Weight Concerns Scale

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 12 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov